ELAVL1 and neoplasm: Wang et al. found that LINC00336 is an oncogene that combines with ELAVL1 to promote tumor cell proliferation, inhibit ferroptosis, and induce tumor formation in an ELAVL1-dependent manner [134]; LINC00618 interacts with lymphoid-specific helicase (LSH) to reduce the expression of SLC7A11, thereby inhibiting ferroptosis [135].